To Evaluate if Dexmedetomidine Infusion Provides Renal Protection in Patients Undergoing Coronary Artery Bypass Graft
Status:
Completed
Trial end date:
2022-01-31
Target enrollment:
Participant gender:
Summary
OBJECTIVE: Aim of this study is to follow and compare the changes in serum creatinine and
urine output up to 48 hours of surgery in patients receiving dexmedetomidine infusion in
addition to standard protocol (Experimental Group) as compared to the patients receiving
standard protocol alone. (Control Group) in patients undergoing isolated coronary artery
bypass grafting surgery (CABG) at a tertiary care cardiac center of Karachi, Pakistan.
STUDY DESIGN: Randomized control trial
PLACE & DURATION OF STUDY: The research will be conducted in the Department of Anesthesia &
Intensive Care, National Institute of Cardiovascular Diseases (NICVD), Karachi. 6 months
(01/08/2021 to 31/1/2022).
DATA COLLECTION PROCEDURE: This study was conducted among 60 patients allocated randomly into
two groups. In the study group (group D), dexmedetomidine was given as an infusion of 0.4
μg/kg/h from induction of anesthesia for 24 hours. In the control group (group C), the
patients were receiving an equal volume of normal saline.
PRIMARY OUTCOME: The primary outcome of the study was Serum Creatinine (mg/dl) which was
measured before the surgery at baseline and then 48 hours after surgery.
SECONDARY OUTCOMES: The secondary outcomes were incidence of urine output per hour for up to
48 hours after surgery, operative time from induction of anesthesia till skin closure, aortic
cross-clamp time from application of aortic cross-clamping till aortic declamping, CPB time
from connecting the patient to extracorporeal circulation till termination of CPB, duration
of ICU stay from transferring the patient from the operating room to the ICU till patient
discharge to the ward, episodes of bradycardia and hypotension, dosage of inotropics and
hemoglobin levels at baseline and up to 48 hours.
KEYWORDS: cardiac surgery-associated acute kidney injury, dexmedetomidine, serum creatinine.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
National Institute of Cardiovascular Diseases, Karachi